Findings from researchers at the University of Michigan Health Rogel Cancer Center, published in Cancer Discovery, show how a specific nucleotide metabolite called GTP controls responses to radiation and chemotherapy in an unexpected way.

Research from the University of Michigan Department of Neurosurgery and Rogel Cancer Center shows promising early results that a therapy combining cell-killing and immune-stimulating drugs are safe and effective in extending survival for patients with gliomas, a highly aggressive form of brain cancer.

A potential drug candidate called ONC201 nearly doubled survival for patients with diffuse midline glioma and DIPG.

Research, led by Michigan Medicine and the University of Michigan, suggests that glioblastoma cells are poised near a “critical point” of order and disorder — meaning, the cells possess some form of large-scale coordination throughout the whole tumor that allows them to respond in practical unison to attempts to kill tumor cells, such as chemotherapy or radiation.

After an awake surgery to remove a cancerous brain tumor, a Michigan man is living “more deliberately” than ever — officiating a high school wrestling state championship and participating in research for a potential cure.

Michigan Medicine researchers used microfluidic devices to track what happens to cancer cells as they migrate and take root in the brain.

Using neuropsychology to heal from cancer treatment: A multidisciplinary clinic uses this method to help patients after oncology treatments

University of Michigan Rogel Cancer Center researchers find ZMYND8 gene plays a critical role in conferring radiation resistance on brain tumors with IDH1 mutation.

Precision oncology approach shows potential for high grade gliomas harboring a genetic mutation.

In mice, researchers have discovered the presence of oncostreams, highly active cells connected to how brain tumors grow and invade healthy tissue.

Findings suggest this method could provide data about tumors sooner than MRIs alone.

The trial advances basic science research on the relationship between purine levels and treatment resistance to develop new treatment options for patients.

Researchers discover how a gene mutation in the cancerous tumor leads to cell cycle dysregulation and heightened sensitivity to a class of inhibitors.

Inhibition of STAT3 signaling may improve survival in those with H3.3G34R/V mutant gliomas, animal studies suggest.

What if a common diabetes medication could help fight a rare type of childhood brain cancer? Recent lab studies reveal metformin shows promising results in suppressing specific tumor types.